About this Research Topic
Immunohistochemical staining is a crucial diagnostic method for determining the hormone receptor-positive status, using the widely adopted 1% nuclear staining cutoff recommended by ASCO/CAP guidelines. However, the expression rate of hormone receptors is of significant importance as a predictor of endocrine therapy efficacy and a prognostic factor. Despite the long-standing discussions regarding the cutoff value, a definitive consensus has yet to be reached. Furthermore, there is a lack of clear criteria for the treatment strategy of hormone receptor-low expression breast cancer, leading to challenges in determining the appropriateness of CDK4/6 inhibitors and chemotherapy as adjuvant therapies.
In this section, we aim to focus on hormone receptor-low expression breast cancer as an emerging and significant subtype. Our goal is to shed light on the fundamental characteristics and clinical aspects of this subtype in greater detail. We aspire to unveil the unique properties and pathological elements associated with this subtype, sharing the latest research findings and clinical data based on these aspects to enhance understanding.
The exploration of new insights into hormone receptor-low expression breast cancer may prove beneficial in the realms of treatment strategies and prognosis assessment. Through this session, we anticipate fostering an exchange of knowledge, contributing to the progress of breast cancer research.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
In this section, we aim to focus on hormone receptor-low expression breast cancer as an emerging and significant subtype. Our goal is to shed light on the fundamental characteristics and clinical aspects of this subtype in greater detail. We aspire to unveil the unique properties and pathological elements associated with this subtype, sharing the latest research findings and clinical data based on these aspects to enhance understanding.
The exploration of new insights into hormone receptor-low expression breast cancer may prove beneficial in the realms of treatment strategies and prognosis assessment. Through this session, we anticipate fostering an exchange of knowledge, contributing to the progress of breast cancer research.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: Breast Cancer, Estrogen Receptor, Progesterone Receptor Hormone, Management, Treatment Approaches
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
